Radioimmunotherapy of lymphoma

1. Research group name/project:
Radioimmunotherapy

2. Group leader and some key members (incl. from other depts./inst.):
Jostein Dahle, Øyvind Bruland, Dag Rune Olsen, Roy Larsen, Trond Stokke, Jørgen Borrebæk, Gro Salberg, Marita Martinsen, Solveig Garman Vik

3. Home address on the internet:
www.radiumhospitalet.no/Stokke

4. Department/Institute:
Department of Radiation Biology
4b. Hospital (HF):
Det norske radiumhospital HF

5. Main aim of research group:
The principal objective of the project is to develop targeted treatment of lymphoma and micrometastatic disease in solid cancers with alpha-emitting radioimmunoconjugates.

6. Some important recent results (with a few key references):
We have shown that it is possible to bind 227Th using chelates and that it is possible to generate a radioimmunoconjugate that can bind to antigen positive cells in vitro. This was considered proof of principle and used for a patent application. Relevant stability of the radioimmunoconjugate has been found. Extensive preclinical evaluation are needed to confirm whether 227Th conjugated via a chelate to an antibody is sufficiently stable to be useful for clinical applications. If an alpha emitting conjugate is successfully developed, the plan is to establish a platform for clinical phase I studies.

7. Methods in current use:Immunoreactivity and binding affinity, cell surivival, cell cycle, apoptosis, studies of uptake in animla and in tumors, therapy of nude mice with xenograft

8. Available equipment:
Flow cytometer, fluorescence microscopes, gammacounter, germaniumdetector.

9. Collaborators:
9.1. Among Helse Sør hospitals :
9.2. Other Norwegian collaborators:
9.3. Collaborators from other countries:

10. Is the group interested in joining a larger collaborative project in Helse Sør:
Yes

11. Tentative name of possible collaborative project(s):
Radioimmunotherapy of lymphoma patients

12. Some key search words:
radioactivity, radioimmunotherapy, alpha-particles, radiation